Cells

Fluorescent protein (FP) tagging is widely used in imaging experiments to investigate the subcellular distribution of proteins. However, because the fluorescence of most FP chromophores is quenched upon their protonation, their fluorescence intensities are dependent on their pKas and on the environmental pH. Thus, the concentration of a protein tagged with EGFP (pKa = 6.0) is dramatically underestimated in the lysosomal lumen (pH ~4.7) compared to that of the same protein tagged with mCherry (pKa = 4.5). In this study, we examined the effect of differential FP tagging on the apparent subcellular distribution of several proteins that reside on the cytoplasmic surfaces of secretory/endocytic organelles. Due to the presumed uniformity of cytoplasmic conditions (pH ~7.2–7.4), we expected to find essentially complete overlap of fluorescent signals, regardless of the nature of the fused FP. However, we were surprised to observe significant discrepancies in the apparent distributions of a subset of proteins tagged with EGFP vs. mCherry (Pearson’s correlation coefficients of about 0.80). These discrepancies were not evident when comparing proteins tagged with mCherry vs. other FPs with low pKas (e.g., mTurquoise (pKa = 4.5), mCerulean (pKa = 3.2)) (Pearson’s correlation coefficients of about 0.90–0.95). Our results suggest that FP tags may be sensitive to the microenvironments on the cytoplasmic surfaces of different organelles.

Immune checkpoint inhibitors have transformed the treatment landscape for advanced melanoma in the past 15 years, delivering unprecedented and durable survival benefits. This success has propelled the development of complementary immune-directed therapies, including cancer vaccines. Among these, synthetic long peptide (SLP) and mRNA vaccine platforms have emerged as highly promising. Advances in next-generation sequencing technology, alongside computational neoantigen algorithm predictions, have enabled patient-specific neoantigen identification to improve vaccine immunogenicity and enhance therapeutic efficacy. Off-the-shelf and personalised SLP and mRNA vaccines have demonstrated the ability to induce robust antigen-specific T-cell responses and modulate the tumour microenvironment. Mechanistically, cancer vaccines synergise with immune checkpoint inhibition. This review outlines the current clinical development of mRNA and peptide vaccines in melanoma, highlighting the significant promise to synergise with immune checkpoint inhibition to enhance efficacy without adding to the systemic toxicity profile. The neoadjuvant setting, characterised by intact tumour antigens and draining lymphatic architecture, offers a compelling biological context for leveraging cancer vaccines for enhanced immune priming and response assessment. Collectively, the rapid advances in technology and emerging clinical data position cancer vaccines as a promising therapy capable of improving immunotherapy in Stage III and IV melanoma.

Mutations in leucine-rich repeat kinase 2 (LRRK2) are among the most common genetic causes of Parkinson’s disease (PD), yet substantial heterogeneity exists among pathogenic variants. How mutations in distinct functional domains of LRRK2 differentially perturb cellular homeostasis remains incompletely understood. Here, we compared two pathogenic LRRK2 mutations—G2019S in the kinase domain and I1371V in the GTPase domain—across multiple cellular models, including SH-SY5Y and U87 cells, and healthy human iPSC-derived floor plate cells. We demonstrate that the I1371V mutation induces markedly more severe cellular dysfunction than G2019S. I1371V-expressing cells exhibited elevated LRRK2 autophosphorylation at S1292 and robust hyperphosphorylation of Rab8A and Rab10, indicating enhanced downstream signaling. These alterations impaired sterol trafficking, leading to selective depletion of membrane cholesterol without changes in total cellular cholesterol. Consequently, I1371V cells displayed increased membrane fluidity, disrupted microdomain organization, altered membrane topology, reduced caveolin-1 expression, and impaired dopamine transporter surface expression and dopamine uptake. Lipidomic profiling further revealed a broad disruption of lipid homeostasis, including reductions in cholesteryl esters, sterols, sphingolipids, and glycerophospholipids, whereas G2019S cells showed comparatively modest changes. Pharmacological intervention revealed mutation-specific responses, with the non-selective LRRK2 modulator GW5074 outperforming the kinase-selective inhibitor MLi-2 in restoring Rab8A phosphorylation, membrane integrity, and dopaminergic function. Collectively, these findings identify membrane lipid dysregulation as a central cell biological mechanism in LRRK2-associated PD and underscore the importance of variant-specific therapeutic strategies.